KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Inventory: 2010-2025

Historic Inventory for Pacira BioSciences (PCRX) over the last 15 years, with Sep 2025 value amounting to $157.7 million.

  • Pacira BioSciences' Inventory rose 40.96% to $157.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.7 million, marking a year-over-year increase of 40.96%. This contributed to the annual value of $125.3 million for FY2024, which is 20.06% up from last year.
  • Pacira BioSciences' Inventory amounted to $157.7 million in Q3 2025, which was up 6.42% from $148.2 million recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' Inventory peaked at $157.7 million during Q3 2025, and registered a low of $64.6 million during Q1 2021.
  • Its 3-year average for Inventory is $114.8 million, with a median of $104.4 million in 2023.
  • Its Inventory has fluctuated over the past 5 years, first surged by 60.45% in 2022, then dropped by 10.31% in 2023.
  • Over the past 5 years, Pacira BioSciences' Inventory (Quarterly) stood at $98.5 million in 2021, then declined by 2.52% to $96.1 million in 2022, then climbed by 8.63% to $104.4 million in 2023, then climbed by 20.06% to $125.3 million in 2024, then spiked by 40.96% to $157.7 million in 2025.
  • Its last three reported values are $157.7 million in Q3 2025, $148.2 million for Q2 2025, and $133.8 million during Q1 2025.